Profile data is unavailable for this security.
About the company
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
- Revenue in CAD (TTM)0.00
- Net income in CAD-25.82m
- Incorporated2017
- Employees10.00
- LocationNervGen Pharma CorpSuite 1703 - 595 Burrard StreetVANCOUVER V7X 1J1CanadaCAN
- Phone+1 (604) 722-5361
- Fax+1 (604) 722-5361
- Websitehttps://www.nervgen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zentek Ltd | 915.32k | -8.19m | 96.77m | 17.00 | -- | 8.07 | -- | 105.72 | -0.0785 | -0.0785 | 0.0088 | 0.1115 | 0.048 | 0.4823 | 5.22 | 53,842.35 | -42.98 | -56.35 | -50.88 | -61.72 | 48.68 | -83.98 | -895.31 | -5,414.02 | 0.5344 | -- | 0.1391 | -- | 2,825.89 | -- | 14.22 | -- | -35.15 | -- |
| Helix Biopharma Corp | 0.00 | -4.88m | 140.54m | 7.00 | -- | 8.75 | -- | -- | -0.0833 | -0.0833 | 0.00 | 0.2104 | 0.00 | -- | -- | -- | -50.07 | -166.45 | -66.34 | -430.79 | -- | -- | -- | -- | -- | -24.39 | 0.0214 | -- | -- | -- | 43.81 | -- | -34.02 | -- |
| Cardiol Therapeutics Inc | 0.00 | -34.78m | 161.94m | 18.00 | -- | 13.26 | -- | -- | -0.4207 | -0.4207 | 0.00 | 0.1093 | 0.00 | -- | -- | 0.00 | -228.34 | -65.44 | -344.00 | -77.84 | -- | -- | -- | -187,932.20 | -- | -- | 0.0138 | -- | -- | -- | -30.39 | -- | -45.03 | -- |
| Satellos Bioscience Inc | 0.00 | -29.77m | 325.86m | 14.00 | -- | 5.28 | -- | -- | -2.29 | -2.29 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -79.17 | -73.24 | -89.12 | -84.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -74.17 | -- | 470.35 | -- |
| NervGen Pharma Corp | 0.00 | -25.82m | 446.94m | 10.00 | -- | -- | -- | -- | -0.3622 | -0.3622 | 0.00 | -0.0401 | 0.00 | -- | -- | -- | -145.30 | -121.67 | -823.55 | -235.16 | -- | -- | -- | -- | -- | -75.72 | -- | -- | -- | -- | -7.25 | -- | -- | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -39.87m | 598.36m | 33.00 | -- | 7.36 | -- | -- | -1.11 | -1.11 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -57.28 | -113.52 | -59.04 | -261.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.63 | -- | 70.91 | -- |
Data as of Feb 11 2026. Currency figures normalised to NervGen Pharma Corp's reporting currency: Canadian Dollar CAD
